Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Study shows how many HBeAg-negative patients can achieve permanent immune control of hepatitis B

More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease.

30 Mar 2023

New review examines link between HDLC and different types of cancer

Researchers summarized studies on the association between high-density lipoprotein cholesterol and different types of cancer

29 Mar 2023

Research uncovers a possible explanation for sex differences in pancreatic cancer

Immunotherapy is an effective form of therapy for different types of cancer. However, for pancreatic cancer, its effect is limited and differs between men and women.

15 Mar 2023

Research identifies western diet-induced microbial and metabolic contributors to liver disease

New research from the University of Missouri School of Medicine has established a link between western diets high in fat and sugar and the development of non-alcoholic fatty liver disease, the leading cause of chronic liver disease.

15 Mar 2023

Specific enzyme produced in liver cancer cells could turn a molecule into potential anticancer drug

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead to the development of a new class of anticancer drugs.

14 Mar 2023

Gut bacteria influence the liver's regenerative ability

When parts of the liver are removed, the body can replace the missing tissue. A team of researchers at the Technical University of Munich has now discovered that the success of this process depends to a large extent on gut bacteria.

1 Mar 2023

Novel fatty liver organoid models could aid in drug discovery and testing

Researchers from the Organoid group (former Clevers group, Hubrecht Institute) together with researchers from the Princess Máxima Center for pediatric oncology established novel human organoid models of fatty liver disease.

23 Feb 2023

Ferroptosis could be the key to making effective immunotherapies against liver cancer

Iron-dependent cell death (ferroptosis) is a type of programmed cell death by means of which the body kills off diseased, defective or superfluous cells.

17 Feb 2023

Researchers highlight the dysregulation of hepatokines in people with NAFLD

Non-alcoholic fatty liver disease (NAFLD) is an important risk factor for type 2 diabetes and cardiovascular diseases.

7 Feb 2023

Study identifies a drug candidate for the treatment of fatty liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases.

3 Feb 2023

New insights on bile duct and gallbladder cancers

Bile duct and gallbladder cancers are uncommon, with an estimated 12,130 new cases diagnosed this year according to the American Cancer Society.

30 Jan 2023

Liver cancer treatment can place significant financial burden on patients, analysis shows

Hepatocellular carcinoma (HCC), the most common type of liver cancer, can place a significant financial burden on patients, according to an analysis led by a researcher at UT Southwestern Medical Center.

30 Jan 2023

Cancer mortality in the U.S. has declined 33% since the 90s

The American Cancer Society has recently published the statistics of cancer incidence and mortality for 2023 in CA: A Cancer Journal for Clinicians.

17 Jan 2023

Eating fast food associated with nonalcoholic fatty liver disease

The new year has begun, and with it, resolutions for change. A study from Keck Medicine of USC published today in Clinical Gastroenterology and Hepatology gives people extra motivation to reduce fast-food consumption.

10 Jan 2023

Review focuses on the link between the pathogenesis and management of hepatocellular carcinoma

A new review was published in Genes & Cancer on December 13, 2022, entitled, "Pathogenesis to management of hepatocellular carcinoma."

9 Jan 2023

Researchers show how liver cancer cells hijack circadian clock machinery to divide and spread

The most common type of liver cancer, hepatocellular carcinoma (HCC), is already the third leading cause of cancer-related deaths globally - and cases are on the rise, both in the U.S. and worldwide.

6 Jan 2023

Researchers discover novel candidate drug targets for advanced non-alcoholic fatty liver disease

Using the latest technologies - including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells - researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).

4 Jan 2023

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

28 Dec 2022

Discovery could pave the way for developing therapies to treat nonalcoholic steatohepatitis

UT Southwestern immunologists have uncovered a key pathogenic event prompted by obesity that can trigger severe forms of nonalcoholic fatty liver disease and potential liver failure.

27 Dec 2022

Exposure to blue-green algae toxin shown to wreak havoc on gut bacteria and cause liver damage

Exposure to a specific type of blue-green algae toxin known as cylindrospermopsin has shown to wreak havoc on gut bacteria and an increased probability of irritable bowel syndrome, inflammatory bowel disease, celiac disease, type 1 diabetes, obesity and inflammation of the liver – a precursor to liver cancer – according to a study led by the University of California, Irvine.

20 Dec 2022